By Dr. Neha Tabassum, MBBS, PhD, MRCP, FHEA
Associate Director, Business Development & Strategy | Agile Clinical Trendz
Every clinical study begins with an ambitious timeline.
Yet, many multicountry studies experience delays long before the first patient is included-not because of protocol complexity or regulatory requirements, but because of one underestimated process:
Site feasibility.
Across Europe, sponsors continue to face increasing pressure to accelerate study delivery while maintaining data quality, regulatory compliance, and budget efficiency. Although advances in digital technologies, AI, and decentralized trial models have transformed many aspects of clinical research, site feasibility remains one of the most critical-and often overlooked-determinants of study success.
Site feasibility is more than patient numbers
One of the most common misconceptions is that site feasibility simply involves identifying investigators with access to eligible patients.
In reality, successful feasibility requires a much broader assessment.
Key considerations include:
- Previous experience with similar therapeutic areas
- Availability of dedicated research staff
- Competing clinical studies
- Ethics committee timelines
- Local regulatory requirements
- Availability of electronic medical records
- Data extraction capabilities
- Language requirements
- Institutional contracting timelines
- Capacity to meet study timelines
A site with a large patient population is not necessarily a site capable of delivering high-quality data within the required timeframe.
Why retrospective studies present unique challenges
Retrospective Real-World Evidence (RWE) studies introduce additional operational complexities.
Unlike prospective clinical trials, retrospective studies depend heavily on the quality, completeness, and accessibility of historical medical records. Differences in electronic health record systems, coding practices, documentation standards, and data governance policies can vary significantly-not only between countries, but also between hospitals within the same country.
For multicountry European studies, additional considerations include:
- GDPR compliance
- Local ethics requirements
- Data anonymization or pseudonymization strategies
- Cross-border data transfer policies
- Language-specific documentation
- Variability in routine clinical practice
Addressing these factors early can substantially reduce downstream delays.
The importance of engaging sites early
Feasibility should begin before the protocol is finalized not after.
Early engagement with investigators helps ensure that:
- Study endpoints are measurable using routine clinical practice data.
- Proposed variables are realistically available.
- Data collection burden is manageable.
- Recruitment assumptions are achievable.
- Operational risks are identified before study initiation.
This collaborative approach often results in protocols that are both scientifically robust and operationally feasible.
Technology can support-but not replace-clinical judgment
Artificial intelligence and digital feasibility platforms are increasingly being used to identify potential sites based on historical performance, publication records, disease prevalence, and electronic health record capabilities.
These technologies can significantly improve efficiency.
However, successful site selection still relies on experienced clinical operations professionals who understand local healthcare systems, investigator engagement, regulatory pathways, and operational realities.
Technology should inform decisions-not replace them.
A strategic rather than administrative process
Sponsors who view feasibility as a strategic planning exercise rather than an administrative task are more likely to achieve:
- Faster study start-up
- Improved site engagement
- Higher-quality data
- Better protocol adherence
- Reduced amendments
- More predictable timelines
Ultimately, investing time in robust feasibility planning often saves considerably more time during study execution.
Looking ahead
As regulatory agencies continue to place greater emphasis on Real-World Evidence to support decision-making, operational excellence will become increasingly important.
Thoughtful feasibility planning is no longer simply the first operational milestone of a study-it is becoming a competitive advantage.
For organisations conducting multicountry observational research across Europe, strengthening feasibility processes today may determine the success of tomorrow's evidence-generation programmes.